Harri A. Järveläinen

1.2k total citations
25 papers, 941 citations indexed

About

Harri A. Järveläinen is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Epidemiology. According to data from OpenAlex, Harri A. Järveläinen has authored 25 papers receiving a total of 941 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Pathology and Forensic Medicine and 8 papers in Epidemiology. Recurrent topics in Harri A. Järveläinen's work include Alcohol Consumption and Health Effects (10 papers), Liver Disease Diagnosis and Treatment (7 papers) and Eicosanoids and Hypertension Pharmacology (6 papers). Harri A. Järveläinen is often cited by papers focused on Alcohol Consumption and Health Effects (10 papers), Liver Disease Diagnosis and Treatment (7 papers) and Eicosanoids and Hypertension Pharmacology (6 papers). Harri A. Järveläinen collaborates with scholars based in Finland, United States and Germany. Harri A. Järveläinen's co-authors include Kai O. Lindros, Che Fang, Magnus Ingelman‐Sundberg, Helmuth Sippel, Markus Perola, Pekka J. Karhunen, Arto Orpana, Vesa Savolainen, Seppo Meri and Antti Väkevä and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Cancer Research.

In The Last Decade

Harri A. Järveläinen

25 papers receiving 906 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Harri A. Järveläinen Finland 16 436 410 265 131 127 25 941
Hide Tsukamoto United States 9 572 1.3× 349 0.9× 529 2.0× 116 0.9× 270 2.1× 10 1.1k
Arumugam Velayudham United States 11 853 2.0× 297 0.7× 500 1.9× 223 1.7× 238 1.9× 11 1.3k
Gladys Ferrere France 9 503 1.2× 194 0.5× 462 1.7× 129 1.0× 134 1.1× 12 980
Adam Kim United States 18 281 0.6× 208 0.5× 288 1.1× 65 0.5× 67 0.5× 34 737
Tim Hendrikx Netherlands 21 812 1.9× 159 0.4× 667 2.5× 238 1.8× 189 1.5× 42 1.6k
Feng Hong United States 11 346 0.8× 122 0.3× 137 0.5× 72 0.5× 311 2.4× 16 1.0k
Lu-Wen Wang China 19 267 0.6× 59 0.1× 342 1.3× 59 0.5× 156 1.2× 48 916
Dongwei Xu China 20 318 0.7× 77 0.2× 516 1.9× 50 0.4× 188 1.5× 47 1.1k
Zbigniew Konopski Norway 16 1.1k 2.6× 145 0.4× 308 1.2× 447 3.4× 433 3.4× 28 1.6k

Countries citing papers authored by Harri A. Järveläinen

Since Specialization
Citations

This map shows the geographic impact of Harri A. Järveläinen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harri A. Järveläinen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harri A. Järveläinen more than expected).

Fields of papers citing papers by Harri A. Järveläinen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harri A. Järveläinen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harri A. Järveläinen. The network helps show where Harri A. Järveläinen may publish in the future.

Co-authorship network of co-authors of Harri A. Järveläinen

This figure shows the co-authorship network connecting the top 25 collaborators of Harri A. Järveläinen. A scholar is included among the top collaborators of Harri A. Järveläinen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harri A. Järveläinen. Harri A. Järveläinen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Järveläinen, Harri A., et al.. (2023). Assessment of the Pharmacokinetics, Disposition, and Duration of Action of the Tumour-Targeting Peptide CEND-1. International Journal of Molecular Sciences. 24(6). 5700–5700. 4 indexed citations
2.
Järveläinen, Harri A., et al.. (2023). Preclinical development of RAG1-40-31L: A novel small activating RNA-lipid conjugate targeting tumor suppressor gene p21 for treatment of non-muscle invasive bladder cancer.. Journal of Clinical Oncology. 41(16_suppl). e16620–e16620. 3 indexed citations
3.
4.
5.
Botta, Gregory P., Tatiana Hurtado de Mendoza, Harri A. Järveläinen, & Erkki Ruoslahti. (2019). iRGD in combination with IL-2 reprograms tumor immunosuppression.. Journal of Clinical Oncology. 37(8_suppl). 55–55. 3 indexed citations
6.
Lindros, Kai O. & Harri A. Järveläinen. (2005). Chronic Systemic Endotoxin Exposure: An Animal Model in Experimental Hepatic Encephalopathy. Metabolic Brain Disease. 20(4). 393–398. 17 indexed citations
7.
Fang, Che, Seokjoo Yoon, Niclas Tindberg, et al.. (2004). Hepatic expression of multiple acute phase proteins and down-regulation of nuclear receptors after acute endotoxin exposure. Biochemical Pharmacology. 67(7). 1389–1397. 67 indexed citations
8.
Väkevä, Antti, et al.. (2004). Protective function of complement against alcohol-induced rat liver damage. International Immunopharmacology. 4(12). 1445–1454. 28 indexed citations
9.
Järveläinen, Harri A., et al.. (2003). L-CARNITINE ALLEVIATES ALCOHOL-INDUCED LIVER DAMAGE IN RATS: ROLE OF TUMOUR NECROSIS FACTOR-ALPHA. Alcohol and Alcoholism. 38(5). 400–406. 44 indexed citations
10.
Järveläinen, Harri A., Antoine Galmiche, & Arturo Zychlinsky. (2003). Caspase-1 activation by Salmonella. Trends in Cell Biology. 13(4). 204–209. 33 indexed citations
11.
Preedy, V. R., Ciprian Neagoe, Harri A. Järveläinen, et al.. (2003). Alcohol Affects the Skeletal Muscle Proteins, Titin and Nebulin in Male and Female Rats. Journal of Nutrition. 133(4). 1154–1157. 32 indexed citations
12.
Järveläinen, Harri A., Antti Väkevä, Kai O. Lindros, & Seppo Meri. (2002). Activation of Complement Components and Reduced Regulator Expression in Alcohol-Induced Liver Injury in the Rat. Clinical Immunology. 105(1). 57–63. 36 indexed citations
13.
Järveläinen, Harri A., et al.. (2001). The antiestrogen toremifene protects against alcoholic liver injury in female rats. Journal of Hepatology. 35(1). 46–52. 43 indexed citations
14.
Järveläinen, Harri A., Arto Orpana, Markus Perola, et al.. (2001). Promoter Polymorphism of the Cd14 Endotoxin Receptor Gene As A Risk Factor for Alcoholic Liver Disease. Hepatology. 33(5). 1148–1153. 107 indexed citations
15.
Hall, Pauline de la Μ., Charles S. Lieber, Leonore M. DeCarli, et al.. (2001). Models of Alcoholic Liver Disease in Rodents: A Critical Evaluation. Alcoholism Clinical and Experimental Research. 25(s1). 254S–261S. 85 indexed citations
16.
Järveläinen, Harri A., et al.. (2000). Kupffer cell inactivation alleviates ethanol-induced steatosis and CYP2E1 induction but not inflammatory responses in rat liver. Journal of Hepatology. 32(6). 900–910. 61 indexed citations
17.
Järveläinen, Harri A., Che Fang, Magnus Ingelman‐Sundberg, & Kai O. Lindros. (1999). Effect of Chronic Coadministration of Endotoxin and Ethanol on Rat Liver Pathology and Proinflammatory and Anti–Inflammatory Cytokines. Hepatology. 29(5). 1503–1510. 101 indexed citations
18.
Lindros, Kai O. & Harri A. Järveläinen. (1998). A NEW ORAL LOW-CARBOHYDRATE ALCOHOL LIQUID DIET PRODUCING LIVER LESIONS: A PRELIMINARY ACCOUNT. Alcohol and Alcoholism. 33(4). 347–353. 63 indexed citations
19.
Nosova, T., K. Jokelainen, Harri A. Järveläinen, Kai O. Lindros, & Mikko Salaspuro. (1998). HIGH BLOOD ENDOTOXIN DOES NOT AFFECT ETHANOL ELIMINATION IN RATS. Alcohol and Alcoholism. 33(5). 443–446. 3 indexed citations
20.
Järveläinen, Harri A., Teija Oinonen, & Kai O. Lindros. (1997). Alcohol‐Induced Expression of the CD14 Endotoxin Receptor Protein in Rat Kupffer Cells. Alcoholism Clinical and Experimental Research. 21(8). 1547–1551. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hide Tsukamoto Breakdown of academic impact, for papers by Arumugam Velayudham Breakdown of academic impact, for papers by Gladys Ferrere Breakdown of academic impact, for papers by Adam Kim Breakdown of academic impact, for papers by Tim Hendrikx Breakdown of academic impact, for papers by Feng Hong Breakdown of academic impact, for papers by Lu-Wen Wang Breakdown of academic impact, for papers by Dongwei Xu Breakdown of academic impact, for papers by Zbigniew Konopski
Rankless by CCL
2026